Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in four abstracts on investigational protein therapeutics sotatercept and luspatercept will be presented by Acceleron, its collaboration partner Celgene and clinical investigators at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held in San Francisco, California on December 6-9, 2014.
Oral presentations | ||
Title: | ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study (abstract #53) | |
Session: | 112. Thalassemia and Globin Gene Regulation: Novel Therapeutic Strategies for Thalassemia - HbF Reactivation and Beyond | |
Date: | Sunday, December 7th | |
Time: | 1:00 pm PST (San Francisco Marriott Marquis, Golden Gate Hall) | |
Title: | ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study (abstract #411) | |
Session: | 637. Myelodysplastic Syndromes – Clinical Studies: Molecular Characterization and Lower Risk MDS | |
Date: | Monday, December 8th | |
Time: | 11:00 am PST (San Francisco Marriott Marquis, Yerba Buena Ballroom Salon 7) | |
Poster presentations | ||
Title: | An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion (abstract #3251) | |
Session: | 637. Myelodysplastic Syndromes – Clinical Studies: Poster II | |
Date: | Sunday, December 7th | |
Time: | 6:00 - 8:00 pm PST (Moscone Center, West Building, Level 1) | |
Title: | Modified ActRIIB-Fc Fusion Protein (ACE-536) Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease (abstract #4055) | |
Session: | 113. Hemoglobinopathies, Excluding Thalassemia – Basic and Translational Science: Poster III | |
Date: | Monday, December 8th | |
Time: | 6:00 - 8:00 pm (PST) (Moscone Center, West Building, Level 1) | |
The posters and presentation slides will be available on Acceleron’s website (www.acceleronpharma.com).
About Luspatercept
Luspatercept is a modified type IIB activin receptor fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-β) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Luspatercept is currently in phase 2 clinical trials in patients with beta-thalassemia and in patients with myelodysplastic syndromes. For more information, please visit www.clinicaltrials.gov.
About Sotatercept
Sotatercept is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-β) superfamily involved in the late stages of erythropoiesis (red blood cell production). Sotatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing sotatercept as part of a global collaboration. Sotatercept is currently in multiple phase 2 clinical trials. For more information, please visit www.clinicaltrials.gov.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
Contacts:
Steven Ertel, 617-649-9234
Senior Vice
President and Chief Business Officer
or
Media
Suda
Communications LLC
Maureen L. Suda, 585-387-9248
